WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H122753
CAS#: N/A
Description: SIR1-365 is a RIPK 1inhibitor
Hodoodo Cat#: H122753
Name: SIR1-365
CAS#: N/A
Chemical Formula: C13H17F2NO2
Exact Mass: 257.12
Molecular Weight: 257.280
Elemental Analysis: C, 60.69; H, 6.66; F, 14.77; N, 5.44; O, 12.44
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: SIR1-365; SIR1365; SIR 1365
IUPAC/Chemical Name: N-(3,5-difluorobenzyl)-N-hydroxy-2,2-dimethylbutanamide
InChi Key: SQPMQJPGOUAGHC-UHFFFAOYSA-N
InChi Code: InChI=1S/C13H17F2NO2/c1-4-13(2,3)12(17)16(18)8-9-5-10(14)7-11(15)6-9/h5-7,18H,4,8H2,1-3H3
SMILES Code: CCC(C)(C)C(N(CC1=CC(F)=CC(F)=C1)O)=O
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 257.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
Alba GA, Ziehr DR, Rouvina JN, Hariri LP, Knipe RS, Medoff BD, Hibbert KA, Kowal A, Hoenstine C, Ginns LC, Lewis GD, Hardin CC. Exercise performance in patients with post-acute sequelae of SARS-CoV-2 infection compared to patients with unexplained dyspnea. EClinicalMedicine. 2021 Aug 28;39:101066. doi: 10.1016/j.eclinm.2021.101066. PMID: 34476393; PMCID: PMC8401400.